Hookipa Biotech, an Austrian biotech startup specialized in developing new generation vaccines, has raised €7m in Series A financing.
Backers include Forbion Capital Partners and Sofinnova Partners.
Founded in July 2011, Hookipa has developed a proprietary technology platform, VaxwaveTM, dedicated to genetic vaccines for the prophylactic and therapeutic treatment of viral diseases.
The company plans to use the funds to advance its lead product HB101 through preclinical development and a Phase I proof of concept study, and to further industrialize and validate the VaxwaveTM technology.
Hookipa Biotech is led by CEO Dr. Katherine Cohen, who was formerly Senior Vice President for Corporate & Business Development at Intercell AG.
FinSMEs
26/10/2011